PL4028002T3 - Przeciwnowotworowe połączenie chidamidu i celekoksybu - Google Patents

Przeciwnowotworowe połączenie chidamidu i celekoksybu

Info

Publication number
PL4028002T3
PL4028002T3 PL19944886.1T PL19944886T PL4028002T3 PL 4028002 T3 PL4028002 T3 PL 4028002T3 PL 19944886 T PL19944886 T PL 19944886T PL 4028002 T3 PL4028002 T3 PL 4028002T3
Authority
PL
Poland
Prior art keywords
chidamide
celecoxib
cancer combination
cancer
combination
Prior art date
Application number
PL19944886.1T
Other languages
English (en)
Inventor
Jia-Shiong Chen
Mu-Hsuan Yang
Cheng-Han Chou
Yi-Hong Wu
Sz-Hao Chu
Ye-Su CHAO
Chia-Nan Chen
Original Assignee
Great Novel Therapeutics Biotech & Medicals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Great Novel Therapeutics Biotech & Medicals Corporation filed Critical Great Novel Therapeutics Biotech & Medicals Corporation
Publication of PL4028002T3 publication Critical patent/PL4028002T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19944886.1T 2019-09-11 2019-09-11 Przeciwnowotworowe połączenie chidamidu i celekoksybu PL4028002T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/105421 WO2021046765A1 (en) 2019-09-11 2019-09-11 An anticancer combination of chidamide and celecoxib

Publications (1)

Publication Number Publication Date
PL4028002T3 true PL4028002T3 (pl) 2026-03-30

Family

ID=74865995

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19944886.1T PL4028002T3 (pl) 2019-09-11 2019-09-11 Przeciwnowotworowe połączenie chidamidu i celekoksybu

Country Status (11)

Country Link
EP (1) EP4028002B1 (pl)
JP (2) JP2022547555A (pl)
KR (1) KR102908068B1 (pl)
CN (1) CN114786672B (pl)
AU (1) AU2019465985B2 (pl)
BR (1) BR112022004471A2 (pl)
CA (1) CA3153597A1 (pl)
ES (1) ES3057788T3 (pl)
MX (1) MX2022002856A (pl)
PL (1) PL4028002T3 (pl)
WO (1) WO2021046765A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322171B (zh) * 2022-08-30 2023-03-17 深圳微芯生物科技股份有限公司 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物
CN119431228B (zh) * 2024-10-29 2025-08-12 成都苑东生物制药股份有限公司 西达本胺晶型i及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103833626B (zh) * 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
IL264068B2 (en) * 2018-01-05 2023-07-01 Great Novel Therapeutics Biotech & Medicals Corp Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells

Also Published As

Publication number Publication date
BR112022004471A2 (pt) 2022-05-31
AU2019465985B2 (en) 2024-05-02
JP2024105304A (ja) 2024-08-06
KR102908068B1 (ko) 2026-01-05
EP4028002C0 (en) 2025-12-17
EP4028002A1 (en) 2022-07-20
CA3153597A1 (en) 2021-03-18
WO2021046765A1 (en) 2021-03-18
CN114786672A (zh) 2022-07-22
ES3057788T3 (en) 2026-03-04
MX2022002856A (es) 2022-03-25
AU2019465985A1 (en) 2022-04-28
EP4028002A4 (en) 2023-06-14
KR20220061179A (ko) 2022-05-12
EP4028002B1 (en) 2025-12-17
CN114786672B (zh) 2024-07-12
JP2022547555A (ja) 2022-11-14

Similar Documents

Publication Publication Date Title
IL293377B1 (en) Hsd17b13 variants and uses thereof
IL282775A (en) Selection of improved tumor reactive t-cells
IL259102A (en) Non-invasive physiological quantification of stress levels
EP3874764A4 (en) TEXT ANNOTATION OF ACOUSTIC EFFECTS
EP3353156A4 (en) AUTOPALMITOYLATION INHIBITORS OF THE TEAD TRANSCRIPTION FACTOR
EP3746071A4 (en) GCN2 INHIBITORS AND THEIR USES
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
IL258997B (en) Honey-cannabinoid therapeutic composition
DK3283107T3 (da) Sammensætninger omfattende en kombination af ipilimumab og nivolumab
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
DK3713554T3 (da) Doseringsanvisninger for vidofludimus til behandling af kroniske inflammatoriske og/eller autoimmunsygdomme
PL3394259T3 (pl) Kompozycje i sposoby zmniejszania ekspresji tau
EP3314503A4 (en) SIMULATION OF AN APPLICATION
DK3182962T3 (da) Compositions and uses of amidine derivatives
PT3645518T (pt) Síntese de omecamtiv mecarbil
DK4335517T3 (da) Indgivelse og dosering af diaminofenothiaziner
JP2018172409A5 (ja) 15−hepeを含む組成物および同組成物を使用する方法
DK3355041T3 (da) Strækbar touchpad af den kapacitive type
LT3448846T (lt) Indazolų sintezė
PL3411021T3 (pl) Nowe zastosowanie kombinacji sakubitrylu i walsartanu
IL281938A (en) Stable semaglutide compositions and uses thereof
HUE049331T2 (hu) Indazolok szintézise
SI3573620T1 (sl) Sestavki za zdravljenje hipertenzije
EP3589734A4 (en) REGULATION OF GENE EXPRESSION BY CLIVING BY RNASE P MODULATED BY APTAMER
DK3927899T3 (da) Nedvibrering af funderinger